Diagnostic accuracy of Enzyme-Linked Immunosorbent Assays to detect anti-Leishmania antibodies in patients with American Tegumentary Leishmaniasis: a systematic review

American Tegumentary leishmaniasis (ATL) is an infectious disease caused by several species of Leishmania. Even though the direct detection of parasites has low sensitivity, it is still the gold standard for the laboratory diagnosis of ATL. Recent studies have shown promising results of Enzyme-Linked Immunosorbent Assays (ELISAs) using recombinant antigens. The aim of this study is to compare the accuracy of ELISAs using novel antigens with the standard ELISA based on soluble antigens of Leishmania (SLA) to diagnose ATL. Studies that analyzed patients with ATL and studies that evaluated the diagnostic accuracy of ELISAs using novel antigens and SLA were included. The Fourteen studies from PubMed, Regional Portal of the Virtual Health Library (BVS), Brazilian Society of Dermatology, Virtual Health Library (IBECS), Literature in the Health Sciences in Latin America and the Caribbean (LILACS), Medical Literature Analysis and Retrieval System Online (Medline), Elsevier Embase, Cochrane Library, The National Institute for Health and Care Excellence (NICE), and Cumulative Index to Nursing and Allied Health Literature (CINAHL) were included. The novel ELISA antigens showed a high sensitivity (93.8%-100%) and specificity (82.5-100%), a better diagnostic performance than SLA-based ELISAs (1-97.4% and 57.5-100%, respectively). Only 10 studies analyzed cross-reactions in serum samples from patients with Chagas disease, and only two studies reported a percentage of cross-reactivity. In this systematic review, the novel ELISA antigens showed better sensitivity and specificity with respect to SLA-based ELISAs. However, a meta-analysis should be performed to confirm this finding

Serologic diagnosis of American tegumentary leishmaniasis caused by different species of Leishmania

A leishmaniose tegumentar americana (LTA) é causada por várias espécies de protozoários do gênero Leishmania e compreende um grupo de doenças que apresentam características clínicas, histopatológicas e imunológicas distintas. O diagnóstico é realizado em base epidemiológica, clínica e patológica, confirmadas por exames parasitológicos positivos e demonstração de hipersensibilidade retardada a antígeno de leishmânia. Os testes sorológicos para o diagnóstico, utilizados até o momento, apresentam várias limitações e por isso é de grande importância identificar proteínas recombinantes de leishmânia, para que sejam testadas como potenciais antígenos para o desenvolvimento de técnicas para o diagnóstico da LTA. Neste estudo, foram utilizadas duas proteínas recombinantes de leishmânia altamente conservadas, Lb8E e Lb6H, derivadas de Leishmania (Viannia) braziliensis (Lb), avaliando a sua capacidade para detectar anticorpos no soro de vários grupos de pacientes por teste imunoenzimático (ELISA). Os antígenos recombinantes reagiram com amostras de 83,3% e 100,0% (Lb6H) dos pacientes com LTA e 95,4% (Lb8E) e 89,4% (Lb6H) dos soros de pacientes de leishmaniose visceral (LV). Em amostras de indivíduos saudáveis, as reações com Lb8E e Lb6H foram altamente específicas. Soros de 219 pacientes com LTA infectados com diferentes espécies de leishmânia prevalentes no Brasil (Leishmania (Leishmania) amazonensis, L. (Viannia) braziliensis, L. (V.) guyanensis e L. (V.) shawi) e amostras de pacientes com outras infecções parasitárias foram avaliados para a presença de anticorpos anti-rLb6H, obtendo-se sensibilidade de 100,0% nas 219 amostras de LTA e especificidade geral de 93,9% (considerando 68 indivíduos saudáveis e 213 pacientes com outras doenças infecciosas). Além disso, as amostras de outras doenças infecciosas indicaram provável ausência de reação cruzada, pois apenas uma minoria de amostras de pacientes com doença de Chagas possuía anticorpos contra rLb6H e essas respostas foram baixas. Enfim, os resultados obtidos sugerem que a técnica de ELISA utilizando o antígeno rLb6H pode ser consideradoa para uso na rotina do diagnóstico sorológico da LTA.American tegumentary leishmaniasis (ATL) is caused by various species of protozoan of the genus Leishmania and comprises a group of diseases that present distinct clinical, histopathological and immunological characteristics. The diagnosis is performed based on epidemiological, clinical and pathological features, supported by positive parasitological tests and presence of delayed hypersensitivity to Leishmania antigens. The serological tests used to date have several limitations and therefore it is of great importance to identify recombinant proteins from Leishmania so that they can be tested as potential antigens for the development of techniques for the diagnosis of ATL. In this study, two highly conserved Leishmania recombinant proteins, Lb8E and Lb6H, derived from Leishmania (Viannia) braziliensis (Lb), were used, evaluating their ability to detect antibodies in the serum of several groups of patients by enzyme-linked immunosorbent assay (ELISA). Recombinant antigens detected 83.3% (Lb8E) and 100.0% (Lb6H) ATL patients, and 95.4% (Lb8E) and 89.4% (Lb6H) visceral leishmaniasis (VL) patients. These reactions with Lb8E and Lb6H were highly specific in healthy subjects. Sera from ATL patients infected with different species of Leishmania, prevalent in Brazil, (Leishmania (Leishmania) amazonensis, L. (Viannia) braziliensis, L. (V.) guyanensis and L. (V.) shawi) and samples from patients with other parasitic infections were evaluated for the presence of anti-rLb6H antibodies. In 219 ATL, the sensitivity was 100.0% e the general specificity, considering 68 healthy subjects and 213 patients with other infectious diseases. In addition, samples from other infectious diseases indicated a probable lack of cross-reactivity, as only a minority of samples from patients with Chagas disease had antibodies against rLb6H and all of these responses were low. Finally, the results suggest that the ELISA using rLb6H antigen may be considered for routine use for serological diagnosis of ATL

Diagnostic accuracy of Enzyme-Linked Immunosorbent Assays to detect anti-Leishmania antibodies in patients with American Tegumentary Leishmaniasis: a systematic review

ABSTRACT American Tegumentary leishmaniasis (ATL) is an infectious disease caused by several species of Leishmania . Even though the direct detection of parasites has low sensitivity, it is still the gold standard for the laboratory diagnosis of ATL. Recent studies have shown promising results of Enzyme-Linked Immunosorbent Assays ( ELISAs) using recombinant antigens. The aim of this study is to compare the accuracy of ELISAs using novel antigens with the standard ELISA based on soluble antigens of Leishmania (SLA) to diagnose ATL. Studies that analyzed patients with ATL and studies that evaluated the diagnostic accuracy of ELISAs using novel antigens and SLA were included. The Fourteen studies from PubMed, Regional Portal of the Virtual Health Library (BVS), Brazilian Society of Dermatology, Virtual Health Library (IBECS), Literature in the Health Sciences in Latin America and the Caribbean (LILACS), Medical Literature Analysis and Retrieval System Online (Medline), Elsevier Embase, Cochrane Library, The National Institute for Health and Care Excellence (NICE), and Cumulative Index to Nursing and Allied Health Literature (CINAHL) were included. The novel ELISA antigens showed a high sensitivity (93.8%-100%) and specificity (82.5-100%), a better diagnostic performance than SLA-based ELISAs (1-97.4% and 57.5-100%, respectively). Only 10 studies analyzed cross-reactions in serum samples from patients with Chagas disease, and only two studies reported a percentage of cross-reactivity. In this systematic review, the novel ELISA antigens showed better sensitivity and specificity with respect to SLA-based ELISAs. However, a meta-analysis should be performed to confirm this finding

Use of Recombinant Antigens for Sensitive Serodiagnosis of American Tegumentary Leishmaniasis Caused by Different Leishmania Species

Submitted by Adagilson Silva ([email protected]) on 2017-06-27T19:33:33Z No. of bitstreams: 1 27927927 2017 sat-use.oa.pdf: 548059 bytes, checksum: 203532deb5164f6376996aeeadd65c0f (MD5)Approved for entry into archive by Adagilson Silva ([email protected]) on 2017-06-27T19:33:55Z (GMT) No. of bitstreams: 1 27927927 2017 sat-use.oa.pdf: 548059 bytes, checksum: 203532deb5164f6376996aeeadd65c0f (MD5)Made available in DSpace on 2017-06-27T19:33:55Z (GMT). No. of bitstreams: 1 27927927 2017 sat-use.oa.pdf: 548059 bytes, checksum: 203532deb5164f6376996aeeadd65c0f (MD5) Previous issue date: 2017-02Fundação Oswaldo Cruz. Instituto Aggeu Magalhães, Recife, PE, BrasilAmerican tegumentary leishmaniasis (ATL) (also known as cutaneous leishmaniasis [CL]) is caused by various species of protozoa of the genus Leishmania The diagnosis is achieved on a clinical, epidemiological, and pathological basis, supported by positive parasitological exams and demonstration of leishmanin delayed-type hypersensitivity. Serological assays are not routinely used in the diagnosis because many are considered to have low sensitivity and the particular Leishmania species causing the disease can lead to variable performance. In the present study, we generated recombinant versions of two highly conserved Leishmania proteins, Leishmania (Viannia) braziliensis-derived Lb8E and Lb6H, and evaluated both in enzyme-linked immunosorbent assays (ELISA). Recombinant Lb6H (rLb6H) had better performance and reacted with 100.0% of the ATL and 89.4% of the VL samples. These reactions with rLb6H were highly specific (98.5%) when compared against those for samples from healthy control individuals. We then assessed rLb6H against sera from ATL patients infected with different species of Leishmania prevalent in Brazil [Leishmania (Leishmania) amazonensis, L (Viannia) braziliensis, and L (V) guyanensis] and samples from patients with other infectious diseases. In analyses of 500 sera, ELISA using rLb6H detected all 219 ATL samples (sensitivity of 100.0%) with an overall specificity of 93.9% (considering healthy individuals and other infectious diseases patients). Only a minority of samples from Chagas disease patients possessed antibodies against rLb6H, and all of these responses were low (with a highest reactivity index of 2.2). Taken together, our data support further evaluation of rLb6H and the potential for its routine use in the serological diagnosis of ATL

Use of Recombinant Antigens for Sensitive Serodiagnosis of American Tegumentary Leishmaniasis Caused by Different Leishmania Species

American tegumentary leishmaniasis (ATL) (also known as cutaneous leishmaniasis [CL]) is caused by various species of protozoa of the genus Leishmania. The diagnosis is achieved on a clinical, epidemiological, and pathological basis, supported by positive parasitological exams and demonstration of leishmanin delayed-type hypersensitivity. Serological assays are not routinely used in the diagnosis because many are considered to have low sensitivity and the particular Leishmania species causing the disease can lead to variable performance. In the present study, we generated recombinant versions of two highly conserved Leishmania proteins, Leishmania (Viannia) braziliensis-derived Lb8E and Lb6H, and evaluated both in enzyme-linked immunosorbent assays (ELISA). Recombinant Lb6H (rLb6H) had better performance and reacted with 100.0% of the ATL and 89.4% of the VL samples. These reactions with rLb6H were highly specific (98.5%) when compared against those for samples from healthy control individuals. We then assessed rLb6H against sera from ATL patients infected with different species of Leishmania prevalent in Brazil [Leishmania (Leishmania) amazonensis, L. (Viannia) braziliensis, and L. (V.) guyanensis] and samples from patients with other infectious diseases. In analyses of 500 sera, ELISA using rLb6H detected all 219 ATL samples (sensitivity of 100.0%) with an overall specificity of 93.9% (considering healthy individuals and other infectious diseases patients). Only a minority of samples from Chagas disease patients possessed antibodies against rLb6H, and all of these responses were low (with a highest reactivity index of 2.2). Taken together, our data support further evaluation of rLb6H and the potential for its routine use in the serological diagnosis of ATL